PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

Synthesis and characterization of folate decorated albumin bio-conjugate nanoparticles loaded with a synthetic curcumin difluorinated analogue

(2017) Kaustubh A. Gawde et al.   JOURNAL OF COLLOID AND INTERFACE SCIENCE

Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug

(2017) Samaresh Sau et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Folate Decorated Nanomicelles Loaded with a Potent Curcumin Analogue for Targeting Retinoblastoma

(2017) Hashem Alsaab et al.   Pharmaceutics

Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities

(2016) KM Morrissey et al.   CTS-Clinical and Translational Science

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis

(2016) Pedro N Aguiar et al.   Immunotherapy

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

(2016) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

(2016) Scott Antonia et al.   LANCET ONCOLOGY

Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy

(2016) Dangge Wang et al.   NANO LETTERS

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

(2015) J. Naidoo et al.   ANNALS OF ONCOLOGY

Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology

(2015) Meagan S. Barbee et al.   ANNALS OF PHARMACOTHERAPY

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells

(2015) Z. Sun et al.   CANCER RESEARCH

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions

(2015) Danielle M. Lussier et al.   JOURNAL OF IMMUNOTHERAPY

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance

(2015) A M Martin et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

(2015) Kim C. Ohaegbulam et al.   TRENDS IN MOLECULAR MEDICINE

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

(2015) A. Ribas   Cancer Discovery

Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status

(2015) Naiyer Rizvi et al.   Journal for ImmunoTherapy of Cancer

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

(2015) Margaret K. Callahan et al.   Frontiers in Oncology

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

(2014) A D'Incecco et al.   BRITISH JOURNAL OF CANCER

Cationic lipid-conjugated dexamethasone as a selective antitumor agent

(2014) Samaresh Sau et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies

(2014) G. K. Philips et al.   INTERNATIONAL IMMUNOLOGY

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

(2014) Yanping Xiao et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cancer cell-selective promoter recognition accompanies antitumor effect by glucocorticoid receptor-targeted gold nanoparticle

(2014) Samaresh Sau et al.   Nanoscale

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

EZH2 as a potential target in cancer therapy

(2014) Michael T McCabe et al.   Epigenomics

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

(2013) S. F. Slovin et al.   ANNALS OF ONCOLOGY

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

(2013) M. Sznol et al.   CLINICAL CANCER RESEARCH

Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment

(2013) Thomas F Gajewski et al.   CURRENT OPINION IN IMMUNOLOGY

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

(2013) Jason R Westin et al.   LANCET ONCOLOGY

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

PD-1 is a novel regulator of human B-cell activation

(2012) Marie-Laure Thibult et al.   INTERNATIONAL IMMUNOLOGY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

(2011) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

Ipilimumab

(2011) Vernon K. Sondak et al.   NATURE REVIEWS DRUG DISCOVERY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH